title: Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.
abstract: Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clinical activity, particularly in lung cancers harboring the EGFR(T790M) mutation, yet acquired resistance to these agents emerges. Additional mutations in EGFR can confer resistance that, depending on their genomic context, could determine new drug sensitivities of the cancer cells.
authors.affiliation: Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Deborah
authors.initials: D
authors.lastname: Ayeni
authors.affiliation: Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. Department of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut. Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut. katerina.politi@yale.edu sarah.goldberg@yale.edu.
authors.forename: Katerina
authors.initials: K
authors.lastname: Politi
authors.affiliation: Department of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut. Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut. katerina.politi@yale.edu sarah.goldberg@yale.edu.
authors.forename: Sarah B
authors.initials: SB
authors.lastname: Goldberg
mesh_terms: D000178:Acrylamides / Q000494:pharmacology*; D000483:Alleles; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics*; D006801:Humans; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
chemical_list: D000178:Acrylamides; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D066246:ErbB Receptors